Evidence map›Paper›PMID 27818782›Full record

ArticleESC heart failure2016

Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure.

Kentaro Jujo, Katsumi Saito, Issei Ishida, Yuho Furuki, Ahsung Kim, Yuki Suzuki, Haruki Sekiguchi, Junichi Yamaguchi, Hiroshi Ogawa, Nobuhisa Hagiwara

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 8 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 8 syntheses or guidelines pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Diuretics in Cardiovascular Disease: For How Long and at What Dose?Journal of cardiovascular development and disease · 2026
    Review
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Kentaro JujoDepartment of CardiologyTokyo Women's Medical UniversityTokyoJapan; Department of CardiologyNishiarai Heart Center HospitalTokyoJapan.ORCID 0000-0002-2011-8204
Katsumi SaitoDepartment of Cardiology Nishiarai Heart Center Hospital Tokyo Japan.
Issei IshidaDepartment of Cardiology Nishiarai Heart Center Hospital Tokyo Japan.
Yuho FurukiDepartment of Cardiology Nishiarai Heart Center Hospital Tokyo Japan.
Ahsung KimDepartment of Cardiology Nishiarai Heart Center Hospital Tokyo Japan.
Yuki SuzukiDepartment of Cardiology Nishiarai Heart Center Hospital Tokyo Japan.
Haruki SekiguchiDepartment of Cardiology, Aoyama Hospital Tokyo Women's Medical University Tokyo Japan.
Junichi YamaguchiDepartment of Cardiology Tokyo Women's Medical University Tokyo Japan.
Hiroshi OgawaDepartment of Cardiology Tokyo Women's Medical University Tokyo Japan.
Nobuhisa HagiwaraDepartment of Cardiology Tokyo Women's Medical University Tokyo Japan.
Avera Heart Hospital · USTokyo Women's Medical University · JPAoyama Hospital Tokyo Women’s Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsLoop diuretics are first-line medications for congestive heart failure (CHF); however, they are associated with serious adverse effects, including decreased renal function, and sympathetic nervous and renin-angiotensin system activation. We tested whether tolvaptan, a vasopressin V2-receptor antagonist, could reduce unfavourable furosemide-induced effects during CHF treatment. METHODS AND

resultsSixty patients emergently hospitalized owing to CHF-induced dyspnea were randomly assigned to receive either 40 mg intravenous furosemide daily or 7.5 mg oral tolvaptan for 5 days after admission. Both groups also received intravenous carperitide and canrenoate potassium. As results, baseline patient characteristics were similar between the furosemide (

conclusionsAs compared with furosemide, tolvaptan in patients with acute heart failure is associated with comparable decongestion, better preservation of renal function and less activation of renin-angiotensin system. (UMIN 000014134).

Indexed as

DiureticHeart failureKidneyPharmacology

Identifiers

PMID27818782
PMCPMC5071712
OpenAlexW2317696856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.